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2Abstract
Glioblastoma multiforme (GBM) is the most common form of primary brain tumors.  It is a
highly aggressive tumor, characterized by an increased proliferation rate and a high capacity to
invade surrounding tissues.  Currently, GBM treatment includes surgical resection followed by
chemotherapy and radiation treatment.  However, these therapeutic options often do not alter the
infiltrative and migratory capacity of GBMs.  The invasive migration of glioblastoma multiforme
has been associated with CD44, a cell surface glycoprotein and the principle receptor for
hyaluronic acid (HA).  The molecular basis of CD44 regulation in GBM is not fully understood.
However, CD44 regulation has been shown to be associated with an AP-1 transcription factor
family member, fos-related antigen 1 (Fra-1), in an equally aggressive cancer, mesothelioma.
Recently, it has also been shown that CD44 expression is linked to Fra-1 expression and activity
in glioma cells as well.
To determine whether malignant brain tumor cell migration is mediated by Fra-1 expression,
wound healing assays were conducted using the A172 GBM cell line and its clones. Compared
to A172 parental cells, which express normal Fra-1 levels, A172-mw6 cells, express a dominant
negative version of Fra-1, which decreases the level of Fra-1.  The A172-mw6 cell line exhibits a
slower migration rate than the A172-mw12 cell line, which contains a vector resulting in
increased Fra-1 expression.  This confirmed that increased Fra-1 expression promotes CD44-
mediated migration of human GBM cells. This study also demonstrated that the MAPK and
AKT/mTOR signaling pathways are involved in regulating the expression and activity of Fra-1
as well as the expression of CD44.  Inhibition of both pathways decreases phosphorylated Fra-1
expression; however, only inhibition of the AKT pathway decreases total Fra-1 and CD44
expression. Moreover, AKT inhibition significantly decreases glioma cell migration, whereas
3MAPK inhibition only slightly decreases the migratory capacity of GBM cells. In conclusion,
the results of this study collectively suggest that: (1) Fra-1 and CD44 expression are regulated by
the MAPK and/or AKT/mTOR signal transduction pathways in GBM; (2) Fra-1 regulates CD44
expression in human GBM cells, which in turn affects glioma cell migration.
4CHAPTER 1
Introduction
Glioblastoma multiforme (GBM) is the most common type of primary brain tumor.
Unfortunately, it is also a Grade IV tumor, characterized by the highest proliferation rate and the
highest capacity to invade surrounding tissues (Wei et al., 2010).  GBM has a yearly incidence
rate of ~16.5 per 100,000 persons.  The grade IV tumor is accompanied with a poor prognosis
and the median survival rate is only 10 to 14 months upon diagnosis (Helseth et al., 2010).
Currently, GBM treatment includes surgical resection followed by chemotherapy and radiation
treatment.  GBM tumors are often resistant or develop resistance to the latter two treatments.
The highly invasive nature of glioma cells often prevents the complete removal of the tumor
during surgical resection, resulting in a greater chance of recurrence (Helseth et al., 2010).  To
improve the prognosis of GBM, the disease must be studied at the molecular level in order to
better understand its infiltrative and migratory nature.
Cell migration is an essential process that underlies the development and functioning of
uni-cellular and multi-cellular organisms.  It is a vital part of many normal and pathogenic
processes including embryogenesis, the immune response, wound healing, and the spread of
cancer (DeLisser, 2009; Kurosaka & Kashina, 2008).  Malignant glioma cells are highly invasive
tumor cells.  There are many underlying factors and mechanisms that regulate the process and
allow glioma cells to metastasize and migrate to surrounding healthy tissue in the brain
(Soroceanu et al. , 1999).  Factors and mechanisms that regulate the process of GBM cell
migration include cell-ECM interactions, direct cell-cell contact, growth factors and other
microenvironmental factors (Claes et al., 2007).  The interaction between adhesion molecules
5present on tumor cells with ECM components results in the degradation of the ECM.  This
allows the cancer cell to migrate and spread to healthy tissue.
The invasive migration of glioblastoma multiforme has been highly associated with the
adhesion molecule CD44.  CD44 is the principle receptor for hyaluronic acid (HA), a major
component of the ECM within the brain.  The molecular basis of how CD44 is regulated in GBM
is not fully understood.  However, CD44 has been shown to be associated with an AP-1
transcription factor, fos-related antigen 1 (Fra-1), in an equally aggressive cancer, mesothelioma
(Ramos-Nino et al., 2007; Ramos-Nino et al., 2003). It has been shown that increased expression
of Fra-1 in mesothelioma cells correlates with increased levels of CD44 expression (Ramos-Nino
et al., 2007).  Fra-1 is also involved in regulating the expression of target genes such as CD44
(Young & Colburn, 2006).  Debinski and Gibo have shown that Fra-1 is often overexpressed in
glioma cells and that the transcription factor plays a role in the cellular transformation of glioma
cells (Debinski & Gibo, 2005).  Fra-1 has been shown to regulate the expression of CD44 in
glioma cells.  It has also been shown that CD44-mediated cell adhesion is promoted by Fra-1
expression and activity (Raines, 2010).  Adhesion is necessary for the migration and invasion of
tumor cells into healthy surrounding tissue; therefore, we must investigate the role of Fra-1
regulated CD44 expression in the invasive migratory behavior of glioblastoma multiforme.
In this study, we investigated the regulation of CD44 expression by Fra-1.  The objective
was to determine whether the expression levels of Fra-1 affect CD44-associated cell migration in
human glioblastoma multiforme cells.  This thesis hypothesizes that decreased expression and
activity of Fra-1 correlates with decreased CD44 expression on glioblastoma multiforme,
resulting in a decrease in the migratory capacity of GBM cells.  To achieve the goals of this
study, the three specific aims were: (1) to determine whether the modulation of Fra-1 and CD44
6affects GBM cell migration; (2) to determine whether Fra-1 regulates CD44 expression through a
MAPK and/or AKT-mediated mechanism; (3) and to determine whether Fra-1 knockdown via




Gliomas are the most common type of primary brain tumors. Glial cells, found in the brain or
spinal cord, are the cells which give rise to gliomas (Children's Brain Tumor Foundation
[CBTF], 2009).  They are known as the supportive cells of the central nervous system (CNS) that
surround neurons, providing insulation, energy, and nutrients.  There are three types of glial
cells: astrocytes, microglia, and oligodendrocytes (Johns Hopkins Medicine, 2011; Yokoyama et
al., 2004). Astrocytes are star-shaped glial cells found in the brain’s capillaries that form the
blood-brain barrier (Johns Hopkins Medicine, 2011). They provide neurons with physical
support by forming a matrix to keep them in place.  Astrocytes also provide nourishment to
neurons by receiving glucose from capillaries and processing the glucose so that it can be used
for energy (Yokoyama et al., 2004).  Another function of the star-shaped glial cells is to remove
neural debris such as dead neurons via phagocytosis.  Microglia, the smallest types of glial cells,
are responsible for “housekeeping” in the central nervous system (Yokoyama et al., 2004).
Microglia constantly move about the central nervous system, recognizing and destroying
damaged or infected neurons, bacteria, viruses, and other infectious agents.  These cells destroy
organisms that have invaded the brain by phagocytosis and by releasing cytotoxic substances
such as nitric oxide and hydrogen peroxide that can directly destroy damaged nerve cells.
Microglia can also produce cytokines such as Interluekin-1 (IL-1) and the tumor necrosis factor
(TNF), which promote the demyelination of axons of unhealthy neurons (Yokoyama  et al.,
2004).  Oligodendrocytes produce a fatty protein called myelin, which surrounds the axons of
nerve cells, forming the myelin sheath.  The myelin sheath provides the axons with insulation
8(Yokoyama et al., 2004). Brain tumors are diagnosed and then named based on a classification
system.  Over the years, there have been several grading systems used to classify tumors of the
central nervous system including the Kernohan’s classification system, the Ringertz
classification system, the St. Anne/Mayo system, and the World Health Organization (WHO)
grading scheme.  The most widely used brain tumor classification system is the WHO grading
system.  The World Health Organization grades tumors on a scale from I to IV, from least to
most malignant, based on their microscopic appearance using the following criteria: atypia
(similarity to normal cells), mitotic index (growth rate), vascularity (blood supply), necrosis
(presence of dead cells in the center of the tumor), and its potential to invade or spread to
adjacent tissues (Johns Hopkins Medicine, 2011). A table describing the WHO tumor grading
system is available in the appendix.
Grade I tumors are the least malignant, grow slowly, and appear to be almost normal
under the microscope.  Grade I tumors are usually cured with surgery alone, and are often
associated with long-term survival (American Association of Neurological Surgeons [AANS],
2006; Johns Hopkins Medicine, 2011).  Grade II tumors grow slightly faster than Grade I tumors
and appear slightly abnormal under the microscope.  Tumors classified as Grade II may spread
into normal surrounding tissue, and can recur as a higher grade tumor.
Grade III tumors are malignant and possess actively reproducing abnormal cells (AANS,
2006). These tumors appear abnormal under the microscope and have the ability to invade
surrounding normal brain tissue.  Grade III tumors recur frequently, often at a higher grade.
Grade IV tumors are the most malignant, and have cells that appear highly abnormal under the
microscope, and reproduce quickly.  Grade IV tumors invade wide areas of adjacent normal
brain tissue, and form new blood vessels in order to maintain its rapid growth (AANS, 2006;
9Johns Hopkins Medicine, 2011).  Glioblastoma multiforme (GBM), the most common,
aggressive, and proliferative brain tumor, is a Grade IV tumor.  Tumors in the central nervous
system often contain several grades of cells.  The highest grade of cells determines the overall
grade of the tumor, even if the majority of the tumor is of a lower grade.
2.2 Glioblastoma Multiforme (GBM) and Current Treatment
Glioblastoma multiforme (GBM) is the most common type of primary brain tumor.
Unfortunately, it is also a Grade IV tumor, the most malignant type, characterized by the highest
proliferation rate and highest capacity to invade surrounding normal tissue (Wei et al., 2010).
Glioblastoma multiforme typically affects adults at 45 years of age and above, and has a yearly
incidence rate of ~16.5 per 100,000 persons.  The median survival rate for individuals with GBM
is 10 to 14 months (Helseth et al., 2010). The recommended treatment of Glioblastoma
multiforme is surgical tumor resection followed by chemotherapy and radiation treatment.  GBM
tumors are often resistant to or develop resistance against radiotherapy and chemotherapy.  The
highly invasive nature of glioma cells often prevents the complete removal of the tumor during
surgical resection resulting in a great chance of recurrence (Helseth et al., 2010).  Therefore,
despite the aggressive multimodal therapy used to treat Glioblastoma multiforme, the disease
remains incurable.  GBM has one of the worst 5-year survival rates among all human cancers
(Krex et al., 2007).  Within two years from the time of primary surgery, almost all GBM patients
will experience tumor regrowth and eventually succumb to the aggressive disease.  However, a
small percentage (<3%) of individuals diagnosed with GBM actually survive for more than 36
months.  These patients are referred to as long-term survivors of Glioblastoma multiforme (Krex,
et al., 2007; Xu et al., 2010).
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There are several medications used to treat or reduce the symptoms of Glioblastoma
multiforme including the two popular drugs of choice, temozolamide (TMZ) and bevacizumab.
Temozolamide is a cytotoxic alkylating agent that, when hydrolyzed, inhibits the replication of
DNA by the methylation of the nucleic acid (Darkes et al. , 2002; Friedman et al., 2000). TMZ
is a small lipophilic molecule with a molecular weight of 194 daltons that is readily absorbed in
the digestion tract, and able to cross the blood-brain barrier (Agarwala & Kirkwood, 2000).
Once the drug reaches an environment with a pH above 7, such as the blood and tissues, TMZ
spontaneously hydrolyzes to the active metabolite methyltriazen-1-yl imidazole-4-carboxamide
(MTIC) (Agarwala & Kirkwood, 2000; Darkes et al., 2002).  MTIC then breaks down rapidly to
an inactive carboxylic acid derivative, 5-aminoimadazole-4-carboxamide (AIC), and a highly
reactive methyldiazonium ion (Darkes et al., 2002).  The methyldiazonium ion methylates the
guanine bases of the DNA molecule, forming O6-methylguanine and N7-methylguanine.  It is the
formation of O6-methylguanine that is responsible for the cytotoxic effects of the chemotherapy
agent.  When enzymes responsible for correcting DNA mismatches attempt to remove O6-
methylguanine, they make single-stranded and double-stranded breaks in the DNA molecule,
causing apoptotic pathways to become active (Agarwala & Kirkwood, 2000).  Although the
initial effects of temozolamide are satisfactory, GBM often becomes resistant to the drug over
time.  There are several cellular mechanisms of resistance for TMZ including defects in DNA
mismatch repair, increased repair of breaks in the DNA strand, and increased removal of alkyl
groups by specific enzymes (Agarwala & Kirkwood, 2000).
Bevacizumab is a humanized monoclonal antibody that targets the protein vascular
endothelial growth factor (VEGF) (Bergsland & Dickler, 2004; Chamberlain, 2011). Many
cancerous cells, including GBM cells, often overexpress VEGF, which stimulates angiogenesis.
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In part, the degree of VEGF expression in Glioblastoma multiforme correlates with the grade and
the aggressiveness of the tumor, as well as the clinical outcome (Chamberlain, 2011).  By
inhibiting VEGF expression, bevacizumab helps to prevent blood vessels from reaching the
tumor, leading to tumor starvation and shrinkage.  However, prolonged treatment with the anti-
angiogenic therapy leads to increased migration and invasion (de Groot et al., 2010).
Bevacizumab leads to major blood vessel remodeling, which results in reduced perfusion and
increased tumor hypoxia (Keunen et al., 2011).  As a result, tumor glycolysis occurs, which leads
to an increase in lactic acid production and to the stabilization of hypoxia-inducible factor-1
alpha (HIF-1 alpha). The hypoxia-inducible factor-1 alpha upregulates the expression of genes
related to cancer aggressiveness such as  the E-twenty-six (ETS) and matrix metalloproteinase
(MMP) family, leading to increased invasion into surrounding normal brain tissue (Keunen et al.,
2011).
Temozolomide was shown to decrease proliferation in two glioblastoma cell lines;
however, the migrational behavior of the glioma cells was unaffected by the drug (Gunther et al.,
2003).  It has also not been shown for bevacuzimab treatment to decrease cancer cell migration.
In fact, chronic exposure of colorectal cancer cells to bevacuzimab has been shown to enhance
cellular migration and invasion (Fan et al., 2011).  Indeed, TMZ and bevacizumab, as well as
other medications, are successful at decreasing or inhibiting the growth of brain tumors.
However, these effects are usually only temporary, due to the tumor cell’s ability to develop
resistance against the drug or to the drug affecting other pathways, causing adverse side effects.
It is essential to do more research in order to better understand the mechanisms that govern the
invasive and migratory nature of Glioblastoma multiforme so that we may develop drugs to
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target a specific pathway without the tumor developing resistance or having adverse effects via
another pathway.
2.3 Invasion and Migration of GBM
Cell migration is an essential process that underlies the development and functioning of
uni-cellular and multi-cellular organisms.  It is a vital part of many normal and pathogenic
processes including embryonic development, the immune response, wound healing, and the
spread of cancer (Kurosaka & Kashina, 2008).  It is crucial for cell migration to be correctly
coordinated during embryogenesis.  Defects in migration may result in severe embryonic
malformations ranging from birth defects to early embryonic lethality (Kurosaka & Kashina,
2008).  Cells of the immune system are recruited and migrate to the site of infection in order to
rid the body of invading pathogens.  If an individual is cut, cells of the immune system including
neutrophils, macrophages, and fibroblasts migrate to the wound and participate in wound
healing.  Cell migration also plays a role in the spread of cancer.  In metastasis, the cancerous
cells migrate from the initial site of tumor growth as single cells or in small groups to healthy
surrounding tissue.
Malignant glioma cells are highly invasive tumor cells.  There are many underlying
factors and mechanisms that regulate the process allowing glioma cells to spread and migrate to
adjacent healthy brain tissue (Soroceanu et al., 1999).  It is believed that highly invasive GBM
cells temporarily go into cell cycle arrest during migratory phases, and therefore become
resistant to the majority of chemotherapy and radiotherapy treatments that are currently available
(Soroceanu et al., 1999).  Once the migrating cells have traveled a certain distance from the
primary tumor, they reenter the cell cycle and form recurrent tumors.  Glioblastoma multiforme
cell migration is a multistep process that requires a number of molecular interactions contributed
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to by the malignant glioma cell, the surrounding extracellular matrix (ECM), and stromal cells
(Geho et al., 2005).  Factors and mechanisms that regulate the process of GBM cell migration
include glioma cell-ECM interactions, direct cell-cell contact, growth factors and other
microenvironmental factors (Claes et al., 2007; Geho et al., 2005).
The migration of glioma cells requires the expression of adhesion molecules, adequate
positioning of these molecules, attachment to its appropriate substrate, and detachment when the
cell moves on (Claes et al., 2007).  CD44 and integrins are major adhesion molecules present on
glioma cells.  Integrins are heterodimeric structures, composed of an α and β subunit, which
extend across the cellular membrane (Domínguez-Giménez et al., 2007) .  The extracellular
domain of integrins recognizes and binds to specific proteins of the extracellular matrix
(Domínguez-Giménez et al., 2007; Geho et al., 2005).  The intracellular domain associates with
specific cytoskeletal adaptor proteins.  Therefore, integrins play an important role in cell
adhesion to the ECM as well as in the transmission of signals from the ECM to the inside of the
cell, which influences multiple cellular activities including migration (Domínguez-Giménez et
al., 2007).  Once glioma cells are attached to the ECM, in order to metastasize, the cancer cell
must degrade the extracellular matrix (Geho et al., 2005).  GBM cells produce proteolytic
enzymes such as matrix metalloproteinases (MMPs) that degrade ECM components.  Once the
tumor cell degrades the ECM, it is able to migrate, spreading to healthy tissue (Claes et al.,
2007).  CD44 is another adhesion molecule that is highly expressed by glioma cells.  CD44 is the
main cell surface receptor for hyaluronic acid (HA).  Increased expression of CD44 correlates
with a higher glioma grade.  Studies have shown that increased expression of the HA receptor
correlates with increased GBM invasion and migration (Claes et al., 2007).
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2.4 The Adhesion Molecule CD44
CD44 is a family of transmembrane glycoproteins encoded by a highly conserved gene
that contains 20 exons (Merzak et al., 1994).  The CD44 proteins are involved in cell adhesion,
cell-cell communication, and signal transduction. Alternative splicing of CD44 mRNA and
posttranslational modifications result in a multitude of CD44 isoforms, which correlates with a
variety of different functions.  Up to 10 variable exons can be inserted into the extracellular
domain during splicing.  The CD44 gene has been mapped to the chromosomal locus 11p13.
The gene is made up of two groups of exons.  Exons 1-5 and 16-20 make up one group, and are
spliced together to form CD44s, the most common isoform.  The other group, exons 6-15, are
known as the variable exons, which can be inserted between exons 5 and 16, forming the variant
CD44 isoforms (Goodison et al., 1999).  The variant exons 6-15 may also be referred to as v1-10
(Bajorath, 2000; Goodison et al., 1999).  The molecular mass of the standard isoform, CD44s, is
approximately 37 kDa; however, the molecular weight is often increased to ~80kDa as a result of
glycosaminoglycan side chain attachment during posttranslational modification (Goodison et al.,
1999; Sneath & Mangham, 1998).  The variant isoform that contains all variant exons (v1-10)
may have a molecular weight of up to 200 kDa (Goodison et al., 1999).
The CD44 protein consists of three regions: a highly conserved C-terminal cytoplasmic
domain, a hydrophobic transmembrane domain, and an extracellular domain which can be
further divided into conserved and nonconserved regions.  The principle ligand of CD44,
hyaluronic acid, as well as other ligands, bind to the extracellular domain of the protein (Figure
2.1) (Goodison et al., 1999).
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Figure 2.1. Structure, binding domains, and interactions of CD44.
There have been several ligands for CD44 that have been identified including chondroitin
sulfate, collagen, fibronectin, osteopontin, growth factors, MMPs,  and the principle ligand,
hyaluronic acid (Bajorath, 2000). Hyaluronic acid is a linear, polymeric glycosaminoglycan and
a major component of the ECM (Bajorath, 2000; Goodison et al., 1999). As shown in Figure
2.2, HA is comprised of repeating D-glucuronic acid and N-acetyl-D-glucosamine dissacharide
units (Bajorath, 2000).  The CD44 protein has at least three HA binding sites, and exists in three
states with respect to binding HA (Misra et al., 2011).  The cell surface receptor may be in a non-
binding state, a non-binding state unless activated by stimuli, or in a constitutively-binding state.
Hyaluronic acid induces signaling within the cell once it binds to CD44 that is constitutively
active (Misra et al., 2011).    The binding capacity of CD44 to hyaluronic acid can be regulated
in a number of ways.  It may be affected by glycosylation and the attachment of
glycosaminoglycan side chains during posttranslational modifications (Goodison et al., 1999).
CD44-HA binding can also be affected by mutations in all regions of the CD44 molecule,
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especially the extracellular domain (Bajorath, 2000).  Many cancer cell types express CD44
variants, which often have a higher affinity to bind to hyaluronic acid (Sneath & Mangham,
1998).  The enhanced ability to bind to HA leads to increased tumorigenecity. All glioma cells
have been shown to express the standard isoform of CD44, which lacks all variable exons.
However, the expression of CD44 splice variants has been reported in one GBM sample (Frank
et al., 1996; Knüpfer et al., 1999).
Figure 2.2. Hyaluronic acid structure segment.
2.5 The Normal Function of CD44
The binding of hyaluronic acid to CD44 initiates, or at least influences, most activities of
the adhesion molecule (Zöller, 2011).  The major function of CD44 is to maintain organ and
tissue structure via cell-cell and cell-ECM adhesion; however, due to the variant isoforms of
CD44, the protein is also involved in other cellular functions including cellular migration,
lymphocyte activation and homing, the presentation of chemokines and growth factors to
migrating cells, as well as in the transmission of growth signals via tyrosine kinases (Bajorath,
2000; Goodison et al., 1999; Naor et al., 2008; Sneath & Mangham, 1998).  CD44 is also
involved in the degradation of hyaluronic acid, and in the transmission of signals mediating
hematopoiesis and apoptosis (Naor et al., 2008).
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The cell surface protein, CD44, plays an important role in cellular migration.  HA
binding to CD44 induces changes in the protein’s membrane localization and conformation,
which triggers the association and activation of various signal transduction molecules and
proteases (Zöller, 2011).  In order for cells to migrate, they must have the ability to overcome the
physical resistance of three-dimensional tissue networks.  Proteases, such as the matrix
metalloproteases (MMPs) family, participate by aiding in the degradation of several extracellular
components including collagen, fibronectin, and laminins (Friedl & Wolf, 2003; Gilles et al.,
2001).  The degradation of ECM components facilitates the migration of normal and tumor cells
to surrounding tissue.
CD44 also plays a crucial role in the body’s immune response, particularly in the process
of inflammation and wound healing (Puré & Cuff, 2001).  CD44 is constitutively expressed on
leukocytes and parenchymal cells including endothelial, epithelial, and smooth muscle cells
(Puré & Cuff, 2001).  Once leukocytes such as T lymphocytes or macrophages have encountered
an antigen, cell surface CD44 expression is transiently upregulated (Goodison et al., 1999;
Zöller, 2011).  The CD44 on T cells may be rapidly activated by cytokines and chemokines that
are produced locally at the sites of inflammation as well (Puré & Cuff, 2001).  The binding of
CD44 on activated T lymphocytes to HA expressed on vascular endothelial cells results in the
activation of T Cell extravasation into sites of inflammation (Goodison et al., 1999; Siegelman et
al., 2000).  CD44-HA interactions contribute to the recruitment of white blood cells from the
bloodstream to the site of inflammation, and initially involves the rolling of activated leukocytes
along the endothelium (Puré & Cuff, 2001).  This leads to the formation of additional adhesive
interactions between leukocytes and endothelial cells that are necessary for firmer binding
(Johnson-Leger et al., 2000; Puré & Cuff, 2001).  Once leukocytes exit the bloodstream and
18
migrate across the endothelium, they move into the sites of tissue damage or infection (Goodison
et al., 1999; Johnson-Leger et al., 2000; Zöller, 2011).
In addition to CD44’s ability to mediate cell adhesion and migration, it also acts as an
activation molecule, and can promote inflammation through the activation of genes involved in
inflammation (Puré & Cuff, 2001).  Studies have shown that the binding of HA to CD44
increases vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1
(ICAM-1) expression on synoviocytes and epithelial cells (Burns et al., 2001; Puré & Cuff,
2001).  The interaction of vascular adhesion molecules such as VCAM-1, ICAM-1, and selectins
with ligands present on the surface of leukocytes (i.e. integrins) regulate diapedesis, which is the
migration of blood cells through intact vessel walls into the surrounding tissue (Foster, 1996).
Through the use of knockout (KO) mice, it has been shown that CD44 plays an important
role in activation-induced cell death (AICD) as well (McKallip et al., 2002).  AICD is the
process in which cells undergo apoptosis in a controlled manner when the cell’s receptor
interacts with a death factor such as the TNF (Maher et al. , 2002).  CD44 knockout mice were
treated with the anti-CD3 monoclonal antibody (mAb), which has been shown to induce T cell
apoptosis.  The treatment of CD44 KO splenocytes with anti-CD3 mAb led to a significantly
reduced level of apoptosis compared to CD44 wild type splenocytes (McKallip et al., 2002).
CD44 expression has also been shown to promote resistance to apoptosis in colon cancer cells
(Lakshman et al., 2004).  Although the findings of the studies are contradictory, showing both
pro- and anti-apoptotic effects of CD44, they still highlight the fact that the cell surface receptor
plays a major role in apoptosis.
CD44 has also been implicated in embryogenesis (DeLisser, 2009; Ponta & Herrlich,
1998; Sherman et al., 1998).  CD44 splice variants, including CD44v3 and CD44v6, play a
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crucial role in limb development by helping to transport a proliferative signal from cells of the
apical ectoderm ridge (AER) to the underlying limb mesenchymal cells.  Interactions between
the AER and limb mesenchyme are necessary in order to establish limb outgrowth and
differentiation (Figure 2.3).  An AER cell secretes fibroblast growth factor-8 (FGF-8).  The
secreted growth factor binds to a CD44 variant protein on the same cell (Sherman et al., 1998).
FGF-8 then binds with high affinity to the FGF receptor present on mesenchymal cells, which
leads to cell proliferation, and subsequent limb development (Sherman et al., 1998).
Figure 2.3. CD44-FGF8 interaction in limb development.
2.6 The Oncogenic Function of CD44
A large number of studies have shown a close correlation between malignancy and CD44
expression, as well as with ECM environments rich in hyaluronic acid.  When hyaluronic acid
binds to the CD44 adhesion molecules present on the tumor cell, tyrosine phosphorylation is
either stimulated or inhibited.  The CD44 of tumor cells interacts with HA-rich
microenvironments, which affects cell signaling pathways that promote the ability of cancer cells
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to migrate, to invade the ECM, and spread to healthy tissue (Misra et al., 2011).  Cancerous cells
often exhibit higher levels of CD44 expression as seen in numerous types of human cancer
including breast, colon, prostate, bladder, ovarian, lung, and brain cancer (Yoshida et al., 2012) .
Many tumor cells express CD44 splice variants that possess a higher binding affinity for HA.
Hyaluronic acid is especially abundant in the white matter tracts of the brain, which are one of
the most common routes of GBM invasion (Wiranowska et al., 2010).  Since the extracellular
matrix of the brain has an abundance of CD44’s principle ligand, HA, it provides the ideal
environment for the glioma cells to migrate and develop new blood vessels (Wiranowska et al.,
2010).   The high amounts of HA in the brain and the overexpression of CD44 by glioma cells
are therefore greatly involved in the migration, invasion, and metastasis of Glioblastoma
multiforme.
CD44 promotes the invasive behavior of cancer through a number of signaling networks.
During crosstalk, the CD44 protein interacts with growth factor receptors such as the epidermal
growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR).  The epidermal
growth factor (EGF), the principal ligand of EGFR (Her1), binds to the extracellular domain of
the receptor, inducing receptor dimerization.  EGFR forms homodimers or heterodimers with
other members of the epidermal growth factor family (Jorissen et al., 2003; Schlessinger, 2002).
Tyrosine autophosphorylation occurs, triggering a network of signaling processes that promote
tumor cell proliferation, migration, adhesion, and angiogenesis, and decrease apoptosis (Arteaga,
2003). A mature hepatocyte growth factor (HGF, also known as scatter factor, SF) protein binds
to the extracellular domain of the HGFR, which is also known as c-Met (You & McDonald,
2008).  Upon ligand binding, c-Met is activated by the autophosphorylation of two tyrosine
residues, Tyr 1234 and Tyr 1235, located in the tyrosine kinase domain (Eder et al., 2009).
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Subsequently, two other tyrosines, Tyr 1349 and Tyr 1356 are phosphorylated (You &
McDonald, 2008).  The phosphorylation of the latter two tyrosine residues leads to the activation
of multiple signal transduction pathways that contribute to tumor survival, growth, and invasion.
Pathways activated by EGFR stimulation include the Src/focal adhesion kinase (FAK) pathway,
the signal transducer and activator of transcription (STAT3) pathway, the mitogen activated
protein kinase (MAPK) pathway, and the phosphoinositide-3-kinase (PI3K)/ AKT pathway.  In
many tumor cells, c-Met expression is activated by HGF through an autocrine loop (You &
McDonald, 2008).  In other words, the cancerous cells continuously produce and secrete HGF,
which bind to the HGF receptor, leading to constitutive activity of many signal transduction
pathways.
Activation of the PI3K pathway plays a vital role in many cellular functions contributing
to the spread of cancer including cell survival, growth, proliferation, and migration (Hennessy et
al., 2005). AKT signaling promotes cell survival by inactivating several pro-apoptotic factors
including the Bcl-2-associated death (BAD) promoter, procaspase-9, and the Forkhead (FKHR)
family of transcription factors (Hennessy et al., 2005).  AKT also promotes cell survival by
activating transcription factors that upregulate anti-apoptotic genes (Zöller, 2011). AKT-
mediated activation of the mTOR pathway also facilitates cell survival and proliferation
(Hennessy et al., 2005).  The binding of CD44 to HA and other ligands also stimulates activation
of the MAPK/ERK pathway, which also has a well-defined role in cancer biology.  The
intracellular signaling pathway is involved in a number of cellular functions including cell
survival, proliferation, cell cycle regulation, angiogenesis, and migration.
In the same manner that immune cells must extravasate to sites of tissue damage or
infection, metastasizing tumor cells must do the same.  In many tumor cells, the upregulated
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expression of CD44 strengthens their binding to hyaluronic acid present on surrounding
endothelial cells, which allows the tumor cells to metastasize and reach healthy tissue (Yoshida
et al., 2012; Zöller, 2011).  Angiogenesis is essential for invasive tumor growth and metastasis.
When CD44 binds to HA, tumors cell produce and secrete proteolytic enzymes that aid in the
degradation of the ECM (Misra et al., 2011).  The binding of CD44 to HA and other ligands
increases the production of growth factors (i.e. VEGF and EGF) by tumor cells.  The growth
factors then recruit surrounding blood vessels and stimulate them to form new vessels in the
tumor.  The new vasculature supplies the tumor with oxygen and nutrients, which promotes
further growth (Hoeben et al., 2004).
The prognosis for patients with glioblastoma multiforme remains poor, which is largely
due to the ability of GBM cells to develop resistance against current drugs (Helseth et al., 2010;
Yoshida et al., 2012).  The CD44 protein has been shown to contribute to drug resistance in
cancer (Cain et al., 2011; Zöller, 2011).  CD44 activated by the binding of HA associates with
the multiple drug resistant 1 (MDR-1) protein (Zöller, 2011).  Increased expression of CD44
correlates with an increased expression of the MDR1 gene, which encodes a P-glycoprotein
(PGP) (Santoni-Rugiu & Silverman, 1997; Zöller, 2011).  PGP is an integral membrane protein
which functions in drug efflux (Santoni-Rugiu & Silverman, 1997).  MDR-1 is expressed in both
normal and tumor cells.  In normal cells, PGP functions to rid the cell of cytotoxic drugs that are
harmful.  In tumor cells, the protein encoded by MDR-1 transports chemotherapy drugs out of
the cell, therefore inhibiting their anti-cancer effects (Santoni-Rugiu & Silverman, 1997; Zöller,
2011).  CD44 also plays a role in drug resistance via the attenuation of the Hippo, JUN N-
terminal kinase (JNK), and p53 pathways.  The weakening of these apoptotic pathways leads to a
decrease in the death of abnormal tumor cells (Zöller, 2011).
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Numerous studies have shown that the CD44 adhesion molecule plays a crucial role in
the invasive and migratory nature of Glioblastoma multiforme (Merzak et al., 1994; Wei et al.,
2010; Wiranowska et al., 2010; You & McDonald, 2008).  However, more research must be
done in order to determine how CD44 expression is regulated by the AP-1 transcription factor,
Fra-1, in GBM.  CD44 regulation was first shown to be associated with the AP-1 transcription
factor in an equally aggressive cancer, mesothelioma, which affects the mesothelium that covers
internal organs such as the heart and lungs (Ramos-Nino et al., 2007; Ramos-Nino et al., 2003).
Ramos-Nino et al. showed that by silencing Fra-1 via shRNA and siRNA, the expression of
CD44 is decreased in mesothelioma cells (Ramos-Nino et al., 2003). It was later shown that Fra-
1 regulates CD44 expression in gliomas via siRNA directed against Fra-1 (Raines, 2010). It is
believed that increased expression of the transcription factor leads to the activation of target
genes that promote the invasion of cancer cells (Ramos-Nino et al., 2007).
2.7 The Normal Function of Fos-related Antigen 1 (Fra-1)
Fos-related antigen 1 (Fra-1) is a member of the activator protein 1 (AP-1) family of
transcription factors, which is involved in a number of cellular processes including cell
proliferation, differentiation, and  programmed cell death (Chiappetta et al., 2007; Chiappetta et
al., 2000; Young & Colburn, 2006).  The transcription factor AP-1 is also involved in regulating
the expression of target genes (Young & Colburn, 2006).  The AP-1 transcription factor family
are dimers consisting of Jun-Jun homodimers or Jun-Fos heterodimers (Figure 2.4) (Young &
Colburn, 2006). Proteins of the Jun family include c-Jun, JunB, and JunD. Members of the Fos
family include c-Fos, FosB, Fra-1, and Fra-2.  AP-1 transcription factors are activated by growth
factors, hormones, cytokines, ultraviolet radiation, and tumor promoters such as the phorbol ester
12-O tetradecanoylphorbol 13-acetate (TPA) (Bamberger et al., 1999; Young & Colburn, 2006).
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The mitogen-activated AP-1 dimer binds to specific DNA sequences in the promoter regions of
target genes, several of which are involved in processes such as cellular proliferation and tumor
invasion (Bamberger et al., 1999).  Studies have shown that Jun-Jun homodimers have little or
no DNA-binding activity depending on the target DNA sequences.  Jun-Fos heterodimers are
more stable and have a higher binding affinity for the promoter regions of target genes than Jun-
Jun homodimers (Bamberger et al., 1999).  The binding of transcription factors to the promoter
region of target genes is necessary for transactivation; therefore, the activity of AP-1 family
members is essential for the activation and regulation of downstream genes.
Figure 2.4. Jun-Fos heterodimer.
The fos-related antigen 1 protein plays a role in the central nervous system, but little is
actually understood about its actual function.  Fra-1 activity is observed in the rat brain during
normal development and following brain injuries in adulthood (Pozas et al., 1999).  During
postnatal development, Fra-1 is expressed in all of the main fiber tracts in the cerebrum, whereas
in adult rats, Fra-1 activity is mainly confined to the hippocampus.  Following brain injuries in
adult rats, Fra-1 is found to be highly expressed in the nuclei of reactive astrocytes, suggesting
that the transcription factor participates in the activation of target genes (i.e. CD44) that function
in repairing brain lesions (Pozas et al., 1999).
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Fra-1 is necessary for formation of the placenta (Eferl et al., 2004; Schreiber et al., 2000).
In order to determine the function of Fra-1 in development, Schreiber et al. developed Fra-1
knockout mice via gene targeting. Fra-1 knockout mice die in utero due to placental defects
during embryogenesis.  The expression of Fra-1 has been shown to be required for placental
vascularization (Schreiber et al., 2000).  If the fetus is not receiving adequate blood flow, it is not
getting enough nutrients or oxygen to remain alive.   After learning that conventional Fra-1
knockout embryos have extraembryonic defects leading to embryonic lethality, Eferl et al.
developed conditional Fra-1 mice in order to define the functions of Fra-1 postnatally.  The
conditional Fra-1 knockout mice were viable and exhibited no major defects as adults, indicating
that the transcription factor is nonessential for most organs.  The mice did however, develop
osteopenia, which is a disease characterized by low bone density  These results suggest that Fra-
1 functions in bone matrix production by osteoblasts and chondrocytes (Eferl et al., 2004).
2.8 The Oncogenic Function of Fra-1
Increased levels of AP-1 activity have been detected in multiple human cancers, which
suggest its role in tumor progression and maintenance (Debinski & Gibo, 2005, 2011; Young &
Colburn, 2006). Several studies have shown that Fra-1 plays an essential role in cellular
transformation and carcinogenesis.  The overexpression of Fra-1 mRNA and protein has been
detected in multiple types of human cancers including lung, colon, breast, prostate, and brain
cancer (Young & Colburn, 2006).  Fra-1 plays a major role in cancer by regulating the
expression of its target genes.  The binding of the transcription factor to its target genes is what
promotes the progression of cancer (Table 2.1) (Verde et al., 2007).
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Table 2.1.
Major Roles of Fra-1 and Implicated Target Genes
Fra-1 Function In Tumorigenesis Target Genes
Cell Proliferation ccdn1, ccna2, p19ARF
Anti-apoptosis Unknown
Cell migration and Invasiveness CD44, c-Met, MMP1,MMP9, uPA
Angiogenesis VEGF-A, VEGF-D
It has been shown that overexpression of Fra-1 contributes greatly to thyroid cell
transformation .  By inhibiting production of the Fra-1 protein via transfection with an antisense
construct, the malignant phenotype of transformed thyroid cells is significantly reduced
(Chiappetta et al., 2000).  This indicates that Fra-1 plays an essential role in the transformation of
cancer cells.  The expression of Fra-1 also stimulates transformation and increases the
invasiveness and motility of epitheloid adenocarcinoma cells.  The cellular transformation of
epitheloid cells was also accompanied by the transcriptional activation of genes associated with
tumor progression including targets of Fra-1, matrix metallopeptidase 9 (mmp9) and urokinase-
type plasminogen activator (uPA) (Kustikova et al., 1998).  The expression of Fra-1 has also
been shown to cause a more malignant phenotype in breast tumor cells.  Increased levels of Fra-1
expression correlate with an increased expression of genes that have been implicated in cancer
progression.  Similar to what is seen in epithelial cancers, these genes include Fra-1 target genes,
mmp9 and VEGF (Belguise et al., 2005).  Increased levels of Fra-1 expression and activity
promote cell proliferation and invasiveness of breast cancer.  Ramos-Nino et al. showed that the
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transformation of mesothelial cells also requires increased Fra-1 expression (Ramos-Nino et al.,
2003).
Debinski and Gibo have shown that Fra-1 modulates the malignant features of glioma
cells as well (Debinski & Gibo, 2005).  GBM cells have a large, flat, and veil-like appearance,
compared to normal epithelial cells, which are small and plump.  Glioma cells are also resistant
to cytotoxic drugs and undergo apoptosis a lot less often than their normal counterparts
(Charalambous et al., 2006).  Exposing glioma cells to ectopic Fra-1 caused phenotypic and
malignant behavior changes in H4 glioma cells, a less aggressive glioma cell line.  The H4
glioma cells do not form tumors in nude mice; however, when the H4 cells were introduced to
ectopic Fra-1, the cells became tumorigenic (Debinski & Gibo, 2005).  Along with the phenotype
of H4 glioma cells, the genotype also changes after exposure to ectopic Fra-1.  Following
exposure, several genes were found to be overexpressed including insulin-like growth factor 3
(IGF-3), IGF-6, JunB, JunD, VEGF, and early growth response 1 (EGR1).  Exposure of glioma
cells to Fra-1 also resulted in decreased expression of a few genes such as N-cadherin and
granulocyte macrophage colony stimulating factor (GM-CSF) (Debinski & Gibo, 2005).  The
overexpression of Fra-1 in glioma cells and in rat fibroblasts stimulates anchorage-independent
growth, which is a main trait distinguishing tumor cells from their normal counterparts
(Chiappetta et al., 2007; Debinski & Gibo, 2005).  Transfection of U-87 GBM cell lines with
sense (+) and antisense (-) Fra-1 alters the morphology and tumor formation in glioblastoma
multiforme.  Compared to U-87 parentals, cells transfected with the antisense Fra-1 transgene
were larger, more rounded, and had fewer and/or shorter processes.  On the other hand, U-
87(Fra-1(+)) cells were more elongated with larger processes.  Debinski and Gibo also showed
that Fra-1 knockdown via Fra-1 siRNA results in a decrease in U-87 MG tumor size.  Compared
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to U-87(Fra-1(-)) clones, the tumor size of normal and Fra-1 (+) transfected cells were more than
six times larger (Debinski & Gibo, 2005).  It has also been shown that a decrease in Fra-1
expression results in a decreased migration rate via wound healing assays of fra-1 siRNA
transfected glioma cells (Debinski & Gibo, 2011).  These results suggest that the transcription
factor plays a major role in glioma cell transformation, tumor growth, and migration.
The AP-1 transcription factor, Fra-1, has been shown to regulate the expression of CD44
in glioma cells.  Fra-1 expression and activity has also been shown to promote CD44-mediated
GBM cell adhesion (Raines, 2010).  Adhesion is necessary for the migration and invasion of
tumor cells into healthy surrounding tissue; therefore, we must investigate the role of Fra-1
regulated CD44 expression in the invasive migratory behavior of glioblastoma multiforme in
order to improve the treatment and prognosis of the disease.
2.9 Research Objectives
The overall objective of the study is to determine whether Fra-1 mediated regulation of
CD44 expression affect cellular migration in Glioblastoma multiforme.  The hypothesis of this
thesis was that overexpression of Fra-1 leads to increased CD44 expression, promoting the
migratory capacity of GBM cells.  The hypothesis of this thesis was based off conclusions from
previous studies, which focused on the role of Fra-1 and CD44 in cancer.  Increased levels of
Fra-1 and CD44 have been detected in multiple human cancers, which suggest their roles in
tumor progression and maintenance (Yoshida et al., 2012; Young & Colburn, 2006).  Debinski
and Gibo have shown that increased Fra-1 expression contributes to the malignant phenotype of
glioma cells (Debinski & Gibo, 2005).  In mesothelioma, Fra-1 and CD44 expression were
shown to be associated.  Furthermore, knockdown of Fra-1 decreased the migration rate of
mesothelioma cells (Ramos-Nino et al., 2007; Ramos-Nino et al., 2003).  CD44 expression has
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also been linked to Fra-1 expression and activity in malignant brain tumor cells. In addition,
CD44-mediated cell adhesion of glioma cells has been shown to be promoted by Fra-1 activity
(Raines, 2010).  In order for tumor cells to migrate, they must adhere to the extracellular matrix.
Upon adherence, the tumor cell is stimulated to secrete proteolytic enzymes, which degrade
components of the ECM, allowing the cancer cell to migrate and invade surrounding healthy
tissue.  Based on these conclusions, this thesis has focused on how the modulation of Fra-1 and
CD44 affects CD44-associated migration in GBM.
To achieve the goals of this study, the three specific aims were: (1) to determine whether
the modulation of Fra-1 expression affects CD44-mediated GBM cell migration; (2) to
investigate whether Fra-1 regulates CD44 expression through a MAPK and/or AKT-mediated
mechanism; (3) and to examine whether decreased expression of Fra-1 via pathway inhibition
prevents glioma cell migration. The findings of the study could lead to a better understanding of
how Fra-1 regulated expression of CD44 affects GBM cell migration, and to the identification of





3.1 Culture and Passage of Glioma Cells
The A172 GBM parentals and clones were a kind gift from Dr. Waldemar Debinski of
Wake Forest University, Winston-Salem, NC.  The cells were grown in Dulbecco’s Modified
Eagle High Glucose 1X Medium (DMEM) (Gibco®), 10% fetal bovine serum (FBS) (Hyclone®),
and 100 µg/mL Penicillin-Streptomycin 1X Solution (Cellgro®).  Each cell line was rinsed with
Dulbecco’s Phosphate Buffered Saline (DBPS) (Gibco®).  The A172-mw12 and A172-mw6 cell
lines were treated with 50 µg/mL G418 Sulfate Solution (Cellgro®) in order to ensure that all




A172-wt Contains no vector; Normal Fra-1 expression levels
A172-v43 Contains empty vector; Normal Fra-1 expression levels
A172-mw6 Contains dominant negative vector that results in decreased Fra-1 expression
levels
A172-mw12 Contains vector that results in increased Fra-1 expression levels
3.2 Western Blot Analysis
Cell lysates were extracted with 1% Trition-X100 (Sigma) and 0.2% Nonidet P-40 (NP-
40) (Sigma) in the presence of a protease inhibitor (Sigma).  Lysates containing proteins were
separated by SDS-PAGE using 8% polyacrylamide gels.  The proteins were then transferred to
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Polyvinylidene Fluoride (PVDF) (Fisher) and blocked for at least one hour with 5% milk in PBS
containing 0.05% Tween 20.  Membranes were incubated with primary antibodies overnight at
4oC while shaking.  The primary antibodies were specific for c-Met, Fra-1 and phosphorylated
Fra-1 (Santa Cruz Biotechnology), and CD44 (R&D Systems). Β-tubulin (Sigma) or actin
(WFU) was used as loading controls.   Primary antibodies were diluted in 5% milk PBS
containing 0.05% Tween 20 as follows: Fra-1 at a 1:1,000 dilution; CD44 at a 1:5,000 dilution;
and β-tubulin or actin at a 1:5,000 dilution.  Following primary antibody incubation, the
membrane was washed three times at 10 minutes each with PBS containing 0.05% Tween 20.
The membrane was then incubated with a secondary antibody conjugated with horseradish
peroxidase, goat anti-mouse IgG (Sigma) or goat anti-rabbit IgG (Sigma), at a dilution of 1:2,000
and 1:2,000, respectively, in 5% milk in PBS containing 0.05% Tween 20 for one hour.
Following secondary antibody incubation, the membrane was washed three times for 10 minutes
each in PBS containing 0.05% Tween 20.  Detection of protein bands was carried out using x-ray
film radiography.
3.3 A172 Cell Migration Assay
The appropriate wells of a 24-well plate were coated with 300 µL of hyaluronic acid
(1mg/mL).  For two hours, the plate was left to air dry under the tissue culture hood.  The 24-
well plate was then placed into the 4oC refrigerator and left overnight.  Following incubation,
each well was blocked with 300 µL of heat inactivated bovine serum albumin (500 µg/mL) for
30 minutes in a 37oC incubator.  The heat-inactivated BSA was then removed, and the plates
were washed twice with 300 µL of BSA (100 µg/mL).  The A172 MG clones (A172-wt, A172-
v43, A172-mw6, and A172-mw12) expressing various levels of Fra-1 were then seeded into each
well and allowed to reach confluence.  Using a 200 µL pipette tip, a wound was scratched down
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the middle of each well.  After wounding, the cells were cultured for 24 hours.  Pictures were
taken at 0hr, 18hr, and 24hr time frames.  The percent closure of the wound between 0hr and
24hr was calculated for each A172 clone using the following equation:
Percent Closure = 100 - [Average wound width at 24hr / Average wound width at 0hr x 100]
3.4 A172 Pathway Inhibition Migration Assay
The appropriate wells of two 6-well plates were filled with 300 mL of DMEM containing
serum and plated with cells that they would be approximately 80% confluent after 24 hours.
After 24 hours, two wounds were made in each well with a 200 µL pipette tip.  After wounding,
the media was aspirated off, and the cells were washed twice with PBS.  The appropriate
treatment was then applied to each well.  Pathway inhibitors were diluted with plus serum
DMEM at a 1:1,000 dilution.  U0126 and LY294002 were used at a concentration of 10 µM and
20 mM, respectively.  After treatment, the cells were then cultured for another 24 hours.  Pictures
of each wound were taken at 0hr and 24hr time frames after treatment with U0126 or LY294002.
The percent closure of the wound between 0hr and 24hr was calculated for each A172 clone
using the equation described above.
3.5 Statistical Analysis
All data was processed using Prism® software.  Duplicate determinations were used per
group, and results were evaluated by one-way analysis of variance using the Newman-Keuls
procedure for comparisons between treatment groups. Differences with p values < 0.05 were
considered statistically significant.
3.6 Quantification of Western Blots
Densitometry was used to measure the relative absorbance values for each band from
western blot analysis.  Adobe® Photoshop (PS) software.  The western blot data was loaded onto
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PS.  The image was inverted and a box was drawn around one band at a time with the Marquee
Tool.  A histogram was then used to obtain the mean and pixel values for each band.  To
calculate the absolute intensity, the value of the mean and pixels were multiplied together.  The
relative intensity value was calculated by dividing the absolute intensity value of each cell line or




4.1 Examine Fra-1 and CD44 Protein Expression Levels in A172 Clones
Western blot analysis was performed in order to ensure that the A172 clones expressed
various levels of Fra-1 expression.  A172-mw6 cells, which contain a dominant negative Fra-1
knockdown vector, exhibited decreased Fra-1 expression levels compared to the A172-wt and
A172- v43 cells that contain an empty vector (Figure 4.1). The A172-mw12 cell line contains a
plasmid with a mutation causing the GBM cells to overexpress Fra-1.  Western blot analysis
shows that these cells overexpress Fra-1 when compared to the A172 and A172-v43 cell lines
(Figure 4.1) (Debinski & Gibo, 2005).
In order to determine whether a decrease in Fra-1 expression subsequently lead to a
decrease in the expression of CD44, the A172-wt and A172-mw6 cells were probed for CD44
and analyzed.  Compared to the A172-wt cell line, the A172-mw6 cells exhibited a lower
expression of Fra-1 as well as CD44 (Figure 4.1 and Figure 4.2).
Figure 4.1. Fra-1 expression in A172-wt and clones.
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Figure 4.2. CD44 expression in A172-wt and A172-mw6 cell lines.
4.2 Examine the Effect of Fra-1 Modulation on GBM Cell Migration
Many studies have shown that Fra-1 promotes tumor cell migration in a number of
different cancer types (Belguise et al., 2005; Kustikova et al., 1998; Luo et al., 2009; Sayan et
al., 2011; Young & Colburn, 2006).  In the following experiment, the A172 cell line and its
vector-containing clones (A172-v43, A172-mw6, and A172-mw12) were utilized to examine
how Fra-1 expression levels affect the migration of GBM cells (Figure 4.3).  The A172-mw6
(Fra-1 dominant negative) cells exhibit a lower percent closure after 24 hours, and therefore a
slower migration rate compared to the A172-v43 controls and the parental A172 cell line.  The
A172-mw12 cell line (Fra-1 overexpressors) exhibits a higher percent closure compared to
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controls.  The percent closure of the A172-mw12 cell line is more than twice that of the A172-
mw6 cells.
Figure 4.3. Modulation of Fra-1 affects A172 GBM cell migration on HA.
4.3 Identification of Pathways Responsible for Fra-1 Regulated CD44 Expression
In order to determine which signal transduction pathways were responsible for Fra-1
mediated expression of CD44 in GBM, A172 parental cells were treated with inhibitors of the
AKT/mTOR and the MAPK pathway. Studies have shown that Fra-1 is an AKT-inducible gene
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in both mesothelioma and prostate cancer (Ramos-Nino et al., 2007).  The PI3K/AKT/mTOR
pathway is capable of regulating a number of cellular functions that promote tumorigenicity
including cell survival, growth, proliferation, as well as inhibiting pro-apoptotic activity (Tiwari
et al., 2003).   Fra-1 expression and its activation by the MAPK pathway have been well
documented in several cancers including colon, lung, and mesothel9ioma (Adiseshaiah et al.,
2005; Jones et al., 2000; Ramos-Nino et al., 2007). The MAPK signal transduction pathway
also plays a role in cellular survival, growth, proliferation, migration, cell cycle regulation, and
angiogenesis.  All of these cellular functions, when gone awry, play a major role in the
development of gliomas.
The stimulation of A172 parental cells with EGF (20 ng/mL) results in an increase of
total Fra-1, phosphorylated Fra-1, and CD44 expression at 4 and 24 hours (Figure 4.4).  A172-wt
cells treated with EGF in the presence of LY294002 (20 µM), a phosphatidylinositol 3-kinase
inhibitor (PI3K) exhibited a decrease in total Fra-1, phosphorylataed Fra-1, and CD44 expression
levels compared to the EGF-treated controls (Figure 4.4A and Figure 4.4C). Cells treated with
EGF in the presence of rapamycin (25nM), an mTOR pathway inhibitor, also exhibited a
decrease in total and phosphorylated Fra-1 and CD44 expression (Figure 4.4A and Figure 4.4C).
A172 GBM cells were also treated with a MEK1/2 inhibitor and MEK1 inhibitor, U0126 (25
µM) and PD 98059 (10 µM), respectively (Figure 4.4B and Figure 4.4D).  Cells treated with the
MAPK pathway inhibitors exhibited a decrease in phosphorylated Fra-1 expression; however,
MAPK inhibition had little to no effect on decreasing total Fra-1 and CD44 expression levels
(Figure 4.4B and Figure 4.4D).
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Figure 4.4. Fra-1 and CD44 expression in A172-wt cells following exposure to MAPK and
AKT/mTOR inhibitors.
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4.4 Pathway Inhibition Affects GBM Cell Migration
Western blot analysis revealed that AKT/mTOR pathway inhibition decreases total and
phosphorylated Fra-1expression as well as CD44 expression in glioma cells.  It also revealed that
MAPK inhibition decreases phosphorylated or active Fra-1, although it has little to no effect on
total Fra-1 or CD44 expression levels (Figure 4.4).  Therefore, the next step was to determine
whether Fra-1 knockdown via pathway inhibition affected GBM cell migration. A172 parental
cells treated with plus serum media in the presence of U0126 (MEK1/2 inhibitor) exhibited a
slight decrease in cellular migration compared to the control cells, treated with plus serum media.
A172 parental cells showed a decreased rate of migration in the presence of the AKT inhibitor,
LY294002 (Figure 4.5).






Glioblastoma multiforme (GBM) is a highly aggressive, grade IV, primary brain tumor
characterized by the highest proliferation rate and the highest capacity to invade surrounding
health tissue (Helseth et al., 2010; Wei et al., 2010).  Unfortunately, GBM is often resistant to or
develops resistance against current treatment, which is surgical resection followed by
chemotherapy and/or radiation treatment.  The invasive migratory nature of glioma cells is the
major driving force behind the aggressiveness of GBM, resulting in a very poor prognosis.
There are many underlying factors that regulate glioma cell migration, allowing them to
metastasize.  The interaction between adhesion molecules present on tumor cells with ECM
components results in the degradation of the ECM.  This allows the glioma cell to migrate and
spread to healthy tissue (Claes et al., 2007).  The adhesion molecule CD44 along with the
transcription factor, Fra-1, were the primary focus of this study.  Specifically, the overall
objective of this thesis was to investigate how Fra-1 mediated regulation of CD44 affects the
migratory capacity of GBM cells.  CD44 was first shown to be linked to Fra-1 in an equally
aggressive cancer, mesothelioma (Ramos-Nino et al., 2007).  A former member of the Martin
laboratory later showed that CD44 expression correlates with Fra-1 expression in GBM as well
(Raines, 2010).
In this study, the regulation of CD44 expression by Fra-1 was reaffirmed via western blot
analysis using A172 MG clones that expressed various levels of Fra-1.  Western blot analysis
was also performed on the A172 parental cell line in order to identify cell signaling pathways
responsible for Fra-1 mediated regulation of CD44.  Wound healing assays were conducted on
A172 clones to demonstrate that CD44-mediated cell migration was regulated by Fra-1, and on
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A172 parentals to demonstrate the effect of MAPK and AKT/mTOR pathway inhibition on the
migration of glioma cells.
5.1 Expression Levels of Fra-1 and CD44 in GBM cells
Debinski and Gibo used western blot analysis to demonstrate that the A172 GBM clones
expressed various levels of Fra-1 (Figure 4.1).  In Figure 4.2, CD44 expression is examined in
the A172-wt and A172-mw6 cell line.  Compared to the A172-wt cells that express normal Fra-1
levels, the A172-mw6 (Fra-1 dominant negative) cell line exhibits a lower level of CD44
expression.  The data from the study shows that decreased expression of Fra-1 correlates with
decreased expression of CD44.  These results were anticipated since it has previously been
demonstrated that Fra-1 knockdown via siRNA in additional glioma cell lines (U-251 MG and
U-1242 MG) results in decreased expression of CD44 (Raines, 2010).
5.2 CD44-Mediated GBM Cell Migration is Regulated by Fra-1 Expression
After determining that Fra-1 expression correlates with CD44 expression in the A172
clones, this study examined whether CD44-mediated migration of GBM cells is regulated by the
AP-1 transcription factor.  In mesothelioma, both Fra-1 and CD44 are linked to cell migration.
Ramos-Nino et al. showed that a decrease in Fra-1 and CD44 expression, via shRNA constructs,
lead to a decrease in the migratory capacity of mesothelioma cells (2007).  These results suggest
that Fra-1 regulates the migration of mesothelioma cells through modulation of CD44 expression
(Ramos-Nino et al., 2007).  Through the use of Fra-1 siRNA, knockdown of Fra-1 has also been
shown to lead to a decrease in the cellular migration of A172 parental cells (Debinski & Gibo,
2011). It has also been shown that Fra-1 knockdown reduces tumor cell migration in breast and
bladder cancer (Luo et al., 2009; Sayan et al., 2011).
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This was the first study to examine whether an increase in Fra-1 expression increases the
migration rate of GBM cells. When Fra-1 is overexpressed, as in the A172-mw12 cell line, the
migration rate of glioma cells increases (Figure 4.3). Similar to a previous study, a decrease in
Fra-1 results in a decrease of the migratory capacity of glioma cells (Debinski & Gibo, 2011).
The results of this study have shown that a decrease in Fra-1 expression correlates with
decreased CD44 expression, leading to a decrease in the migratory capacity of brain tumor cells.
Collectively, these results suggest that the modulation of Fra-1 affects CD44-mediated migration
of glioma cells.
5.3 MAPK and AKT/mTOR Inhibition Decreases Fra-1 and CD44 Expression
In this thesis, we focused on whether Fra-1 expression in human GBM cells is regulated
by the AKT/mTOR and MAPK cell signaling pathways.  In Figure 4.4A, inhibition of the
AKT/mTOR pathway using the PI3K inhibitor, LY294002 (20 µM) and the mTOR inhibitor,
rapamycin (25 nM), caused a reduction of overall Fra-1, phosphorylated Fra-1, and CD44
expression in A172 GBM cells.  Glioma cells treated with U0126 (25 µM), a MEK 1/2 inhibitor,
and PD98059 (10 µM), a MEK1 inhibitor, also exhibited decreased expression of
phosphorylated Fra-1 (Figure 4.4B); however, there was minimal change in the expression levels
of total Fra-1 and CD44. The results gathered in the study agree with findings in mesothelioma.
Inhibition of PI3K and MEK1 with LY294002 (20 µM) and PD98059 (30 µM), respectively,
caused significant reduction of Fra-1 mRNA levels in numerous mesothelioma cell lines
(Ramos-Nino et al., 2007). The results of this research suggest that CD44 expression is
regulated by Fra-1 in an AKT/mTOR dependent manner, and that MAPK regulated Fra-1 has
virtually no effect on CD44 expression in GBM cells. In GBM, AKT/mTOR regulated Fra-1
appears to stimulate the transcription of CD44, which in turn greatly affects the migratory
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capacity of glioma cells.  It is also possible that AKT-regulated Fra-1 activates transcription of
other genes involved in cell migration and invasion such as uPA/uPAR, MMP3, and MMP9
(Kustikova et al., 1998).  Studies have shown that MAPK inhibition decreases cellular
proliferation in glioma cells, and it is believed that inhibition of MAPK affects the proliferative
capacity of glioma cells more than other cellular functions (Huang et al., 2009; Zohrabian et al.,
2009).  Therefore, MAPK regulated Fra-1 may activate the transcription of genes that promote
tumor cell proliferation (Kustikova et al., 1998).
5.4 Fra-1 Knockdown Via Pathway Inhibition Decreases GBM Migration
After observing that MAPK and AKT/mTOR pathway inhibition decreases Fra-1
phosphorylation (Figure 4.4), the next step was to identify whether this knockdown affected the
migratory capacity of human GBM cells since both pathways have been implicated in cellular
migration (Hennessy et al., 2005). In order to determine if pathway inhibition affects glioma
cell migration, wound healing assays were performed on the A172 parental cell line. The results
indicate that MAPK and AKT pathway inhibition decreases the migratory capacity of glioma
cells (Figure 4.5).  However, AKT inhibition had a more pronounced effect on decreasing
cellular migration, whereas MAPK inhibition resulted in only a slight decrease when compared
to controls.  The average percent closure after 24 hours of the control cells treated with plus
serum media was similar to that of cells treated with the MAPK inhibitor, U0126.  However,
inhibition of the AKT/mTOR pathway via LY294002 resulted in a percent closure of that was
significantly lower compared to the controls (Figure 4.5B).  Generally, MAPK is the dominant
signaling pathway associated with proliferation, whereas the AKT pathway is usually involved in
tumor cell invasion (Nakada et al., 2011). These results suggest that AKT-regulated Fra-1 may
play a bigger role in migration, and that MAPK-regulated Fra-1 plays more of a prominent role
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in the proliferation of glioma cells.  This thesis proposes that MAPK and AKT/mTOR-regulated





The research of this thesis confirms that the AP-1 transcription factor, Fra-1, and the cell
surface protein, CD44, play an important role in glioma cell migration.  Overexpression of Fra-1
and CD44 is characteristic of many tumor cell types.  A wound healing assay confirmed that
increased Fra-1 expression promotes CD44-mediated migration of human GBM cells.  This
study has also demonstrated that both MAPK and AKT/mTOR pathway inhibition decreases Fra-
1 phosphorylation. However, only AKT inhibition results in noticeable decreases of total Fra-1
and CD44 expression levels.  It has also been shown that AKT inhibition significantly decreases
glioma cell migration, whereas MAPK inhibition only slightly decreases the migratory capacity
of GBM cells.
It has now been shown that Fra-1 regulates not only CD44-mediated adhesion of glioma
cells, but migration as well.  However, more research must be done in order to determine
whether Fra-1 is directly linked CD44 expression in Glioblastoma multiforme.  This could be
demonstrated via a chromatin immunoprecipitation (ChIP) assay, which would be used to
determine whether CD44 expression is directly linked to Fra-1 by examining whether the
transcription factor actually binds to the promoter region of CD44, leading to its activation and
regulation.  Future studies should also focus on determining the role of MAPK-regulated Fra-1 in
GBM.  An MTT assay could be conducted in order to examine whether MAPK regulated Fra-1
plays a major role in glioma cell proliferation.  Real-time PCR studies may also be conducted in
order to determine whether mRNA expression of CD44 is regulated by Fra-1 as well.
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Appendix
World Health Organization Grading Scheme
Grade Characteristics Tumor Types
I  Least malignant
 Grow slowly
 Cell appear almost normal under microscope




II  Relatively slow growing
 Cells appear slightly abnormal under microscope
 May spread into healthy surrounding tissue





 Actively reproduces abnormal cells
 Cells appear normal under microscope
 Spreads to surrounding healthy tissue





IV  Most malignant
 Actively reproduces abnormal cells
 Cells appear very abnormal under microscope
 Easily spreads into healthy surrounding tissue
 Angiogenesis occurs rapidly
 Necrosis
 Glioblastoma
multiforme (GBM)
 Medulloblastoma
